If you couldn't get a piece of the largest IPO in history a couple of weeks ago, you were far from alone.
I think the Alibaba Group Holding Ltd. (NYSE: BABA) initial public offering will go down as the greatest wealth opportunity of a generation - but only about 4% of the $25 billion worth of stock went to individual investors like you.
As alluring as Alibaba and the white-hot IPO market can be, it's not a place to play unless you have the "connections" needed to access the best deals - or have a special "angle" to play.
I can't help you with the connections. But I can give you that special angle.
And that angle will give you access to the profits rolling out of Alibaba and the IPO market - but at a much lower level of risk.
So today I'm going to show you a far better way to gain access to Alibaba's huge profit stream at a nearly 50% discount from the stock's current price - and at a much lower level of risk.
And I think you'll beat the overall market by some 80% over the next two years...
The Lifeblood of Silicon Valley
As a tech insider and someone who's watched and profited from IPOs for years, I know that Silicon Valley runs on IPOs. The promise of buckets of IPO cash is why venture capitalists back promising tech companies in the first place.
Not only that, but a healthy IPO market is good for stocks in general.
Bull markets like the one we're in run on fresh cash flowing in. And there's nothing quite like an IPO to keep investors buying stocks.
The good news here is the IPO market right now is the healthiest it's been in years.
According to Dealogic, the Alibaba IPO brought the value of deals so far this year to $69 billion. That's up 11.2% from the same period last year and puts it on pace to be the best year for IPOs in a decade.
In other words, Alibaba had a successful IPO in a great climate for new issues - and all that bodes well for the market as a whole.
But for retail investors, Alibaba represented three negatives.
Here Are 10 “One-Click” Ways to Earn 10% or Better on Your Money Every Quarter
Appreciation is great, but it’s possible to get even more out of the shares you own. A lot more: you can easily beat inflation and collect regular income to spare. There are no complicated trades to put on, no high-level options clearances necessary. In fact, you can do this with a couple of mouse clicks – passive income redefined. Click here for the report…
About the Author
Michael A. Robinson is a 36-year Silicon Valley veteran and one of the top tech and biotech financial analysts working today. That's because, as a consultant, senior adviser, and board member for Silicon Valley venture capital firms, Michael enjoys privileged access to pioneering CEOs, scientists, and high-profile players. And he brings this entire world of Silicon Valley "insiders" right to you...
- He was one of five people involved in early meetings for the $160 billion "cloud" computing phenomenon.
- He was there as Lee Iacocca and Roger Smith, the CEOs of Chrysler and GM, led the robotics revolution that saved the U.S. automotive industry.
- As cyber-security was becoming a focus of national security, Michael was with Dave DeWalt, the CEO of McAfee, right before Intel acquired his company for $7.8 billion.
This all means the entire world is constantly seeking Michael's insight.
In addition to being a regular guest and panelist on CNBC and Fox Business, he is also a Pulitzer Prize-nominated writer and reporter. His first book Overdrawn: The Bailout of American Savings warned people about the coming financial collapse - years before the word "bailout" became a household word.
Silicon Valley defense publications vie for his analysis. He's worked for Defense Media Network and Signal Magazine, as well as The New York Times, American Enterprise, and The Wall Street Journal.
And even with decades of experience, Michael believes there has never been a moment in time quite like this.
Right now, medical breakthroughs that once took years to develop are moving at a record speed. And that means we are going to see highly lucrative biotech investment opportunities come in fast and furious.
To help you navigate the historic opportunity in biotech, Michael launched the Bio-Tech Profit Alliance.
His other publications include: Strategic Tech Investor, The Nova-X Report, Bio-Technology Profit Alliance and Nexus-9 Network.